NASDAQ: ANEB
corporate presentation
November 2022
Cautionary Note Regarding Forward-Looking Statements
Forward-Looking Statements
This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements use terms such as “anticipate,” “anticipate,” “intend,” “could,” “will,” “should,” and other Along with equivalent terms, they involve risks and uncertainties as they relate to and depend on events. About future situations. These statements include statements regarding the intentions, beliefs, or current expectations of Anebulo Pharmaceuticals and its management, and the assumptions upon which such statements are based. Future investors are cautioned that such forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties.-K and other periodic reports filed with the SEC and actual results may differ materially from those intended by such forward-looking statements. Except as required by federal securities laws, Anebulo Pharmaceuticals undertakes no obligation to update or revise any forward-looking statements to reflect changing circumstances.
Recipients should be careful not to place undue reliance on these statements. Please also note that the foregoing statements may not include all of the forward-looking statements made in this presentation. We undertake no obligation to publicly update these forward-looking statements, except as required by law.
Market and industry data
This presentation includes market and industry data and forecasts that we have prepared from independent research reports, public information, various industry publications, other public industry sources, or our internal data and estimates. I’m here. Although independent research reports, industry publications, and other publicly available industry sources generally indicate that the information contained therein was obtained from sources believed to be reliable, such information does not guarantee its accuracy or completeness. While we believe our publications and reports to be reliable, we have not independently verified the data and make no representations or warranties as to the accuracy of such information. All trademarks and trade names mentioned in this presentation are
property of their respective owners. Our internal data, estimates and forecasts are based on information obtained from trade and business organizations and other agreements in the markets in which we operate and management’s understanding of industry conditions. While we believe such information to be reliable, we have not verified such information by an independent source.
Anebro overview
- Biopharmaceutical companies developing novel antidotes for acute cannabinoid intoxication and, in the longer term, other indications related to abuse and addiction
- ANEB-001Believed to reverse the adverse effects of acute cannabinoid intoxication within 1 hour of administration
-
- Potent small molecule CB1 antagonist with high affinity for the human CB1 receptor
- Completed clinical trials show ANEB-001 is rapidly absorbed and well tolerated
- Phase 2 Cannabinoid Addiction Proof-of-Concept Study Begins with Topline Results Expected in H1 2022
- May 6, 2021 IPO raises total of $21 million
- Cash runway to CY24
- 23.4 million shares outstanding
3
investment highlights
Addressing an unmet medical need to treat acute cannabinoid intoxication, a large and growing market
• There are no products approved for this indication and no other compounds progressing to clinical trials
• Nearly 1.7 million cannabinoid-related emergency room (ED) visits in the US in 2019, an increase of 15% each year
- Legalization of medical and recreational cannabis is driving addiction and hospital ED visits
ANEB-001 is a risk-free asset with a well-understood mechanism of action
• In-licensed from Vernalis, a (former) subsidiary of Ligand Pharmaceuticals
• Central actions of THC are CB1-mediated and ANEB-001 is a CB1 antagonist
- Demonstrated in a Phase 1 study ANEB-001 is rapidly absorbed, well tolerated, and crosses the blood-brain barrier.
Fast path to proof of concept
• Phase 2 proof-of-concept study launched with topline results announced in September 2022
• Ongoing studies in the Netherlands (experienced with these types of trials)
- Be expected Short-term news streams with key value creation milestones
A capital efficient business model
• Clinical research and data management outsourcing
• Seeking strategic alliance for commercialization
Four
leadership
|
business administration |
Dr. Ken Cundy |
|
|
Simon Allen |
Rex Merchant, CFA |
|
|
Chief Scientific Officer |
||
|
Chief executive officer |
CFO |
|
|
Since I started in Gilead’s lab |
JFL Capital Management, |
Extensive experience in drug discovery and preclinical |
|
and clinical development, product approval |
||
|
20 years of experience in sell-side business development and |
||
|
Western Investment, Benchmark Plus |
||
|
For over 30 years, various |
||
|
leadership |
||
|
Including corporate and blockbuster drugs, etc. |
||
|
Ambrx Biopharma, CovX, Skypharma, Kalypsys |
||
|
Stanford University |
As Gilead’s HIV drug tenofovir |
|
|
Gilead Sciences |
Over 15 INDs and 6 NDAs |
|
|
University of Sydney |
University of Manchester, University of Kentucky |
|
|
Australian School of Management |
||
board of directors
|
Joseph Lawler |
Simon Allen |
Aaron English |
Jason Allier |
Aleta Kupchik |
Dr. Nat Calloway |
Ken Lin, M.D. |
Carla Perschauer |
|
medical doctor |
|||||||
|
Founder, Chairman |
Chief executive officer |
Affiliated director |
Outside Director |
Outside Director |
Outside Director |
Outside Director |
Outside Director |
|
general partner |
Ambrx Biopharma, CovX, |
general partner |
general partner |
|
JFL Capital Management |
Sky Pharma, Calypsis, |
22NW |
JALAA stock, |
|
Gilead Sciences |
officer ligand |
||
|
pharmaceuticals |
|
FDA Attorney, Partner Foley |
analysts and partners |
Former CEO Abu Inishio |
|
Hoag, Former Associate |
22 Northwest |
biopharmaceutical, ex |
|
Chief Drug Attorney |
Cornell University and |
Corporate Vice President |
|
and FDA biologics |
Columbia University |
Development/Investor Relations |
|
Ulthera |
||
|
Five |
legal adviser
Ultragenyx-Board
with member Evoras
Arcturus
Former Legal Officer
compliance
Allergan
This is an excerpt of the original content. To read more, visit the original document here.
Disclaimer
Anebro Pharmaceutical Co., Ltd. I published this content on November 20, 2022 You are solely responsible for the information contained therein. It will not be edited or modified and will be distributed by the public. November 20, 2022 15:28:04 UTC.
Public Now 2022
|
|
||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
||||
|
||||
Income Statement Evolution
|
sell  buy |
|
| average consensus | buy |
| number of analysts | 2 |
| Final closing price | 2,40$ |
| average target price | 8,00$ |
| Spread/Average Target | 233% |
